Previous close | 10.26 |
Open | 10.26 |
Bid | 9.66 x 100 |
Ask | 9.73 x 100 |
Day's range | 9.70 - 10.26 |
52-week range | 6.30 - 11.92 |
Volume | |
Avg. volume | 120,725 |
Market cap | 270.015M |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.60 |
Earnings date | 09 May 2024 - 13 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 18.33 |
When you buy a stock there is always a possibility that it could drop 100%. But when you pick a company that is really...
Fennec Pharmaceuticals Inc (NASDAQ:FENC), a biopharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric cancer patients, has reported a significant insider sell transaction.
Robert Andrade, the Chief Financial Officer of Fennec Pharmaceuticals Inc (NASDAQ:FENC), has sold 13,975 shares of the company on March 26, 2024, according to a recent SEC Filing.